Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Quest Diagnostics Inc (DGX) vs Lumen Technologies Inc (LUMN) Price & Performance

Quest Diagnostics IncTrade
Lumen Technologies IncTrade

Price performance (Past 24H)

Key statistics

Quest Diagnostics Inc vs Lumen Technologies Inc — how do they compare? Quest Diagnostics Inc trades at $204.94 (market cap $22.80B), while Lumen Technologies Inc trades at $6.49 (market cap $6.56B). The key difference: Quest Diagnostics Inc is far larger — about 3.5× Lumen Technologies Inc's market cap, and Quest Diagnostics Inc pays a 1.67% dividend while Lumen Technologies Inc pays none. Which is the better fit depends on your goals.

DGXLUMN
Market Cap
$22.80B$6.56B
Sector
HealthMedia
52-Week High
$216.02$11.83
52-Week Low
$166.42$3.70
Enterprise Value
$28.82B$18.19B
Dividend Yield
1.67%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Quest Diagnostics Inc

Quest Diagnostics (DGX) trades at $207.35, showing minimal daily movement with a slight decline of 0.04%. The stock maintains a bullish technical stance with recent earnings beats and analyst consensus pointing to upside potential. Recent developments include New York State approval for Haystack MRD testing and strong momentum across diagnostic channels. Revenue growth accelerated to $11.04 billion in 2025 with consistent profitability margins around 9%.

DGX presents a balanced investment case with 38% analyst buy ratings and a $227.75 price target suggesting 10% upside. The company demonstrates steady revenue growth and operational efficiency, though elevated debt levels and policy risks require monitoring. Second quarter earnings on July 23, 2026, will be crucial for validating current momentum and growth trajectory.

Lumen Technologies Inc

LUMN trades at $6.45, down 4.16% today, reflecting ongoing investor caution amid a bearish technical signal. The company reported a net loss of $1.74 billion in 2025 despite beating earnings expectations in two of the last three quarters. Recent news highlights strategic moves like the Alkira acquisition to bolster its AI networking platform. Cash flow from operations remains strong at $4.74 billion, but high debt levels and negative profitability metrics pose challenges.

The outlook is mixed; cost-cutting and a $13 billion contract backlog offer potential upside, but persistent losses and a heavy debt load of $17.49 billion limit near-term growth. Analyst consensus is cautious with a hold-heavy rating, though the $8.25 price target implies modest upside from current levels if execution improves.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Quest Diagnostics Inc

Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.

Read more on DGX

About Lumen Technologies Inc

With 450,000 route miles of fiber, including over 35,000 route miles of subsea fiber connecting Europe, Asia, and Latin America, Lumen Technologies is one of the United States' largest telecommunications carriers serving global enterprises. Its merger with Level 3 further shifted the company's operations toward businesses (over 70% of revenue) and away from its legacy consumer business. Lumen offers businesses a full menu of communications services, providing colocation and data center services, data transportation, and end-user phone and internet service. On the consumer side, Lumen provides broadband and phone service across 37 states, where it has 4.5 million broadband customers.

Read more on LUMN